Client Identifier: SANOFISYNTHELABO/RESEARCH428
Date of Request: 12/17/99
The Current Database is WPI
Your Terms and Connectors Query:

PN("WO 9717064!")

199725
Stabilised lyophilised composition existing as mixture of amorphous and crystalline phases - contains non-protein pharmaceutical and synergistic combination of mannitol and alanine as stabiliser, providing stability for drug in aqueous solution
Patent Assignee: SANOFI SA (SNFI)
Inventor: BOULOUMIE C; BREUL T; COLLIERE L; FAURE P; BOULOMIE C
Number of Countries: 076
Number of Patents: 013
Patent Family:
Patent No Kind Date Applicat No Kind Date Main IPC Week
WO 9717064 A1 19970515 WO 96FR1706 A 19961030 A61K-009/19 199725 B
FR 2740686 A1 19970509 FR 9513022 A 19951103 A61K-047/42 199726
AU 9674990 A 19970529 AU 9674990 A 19961030 A61K-009/19 199737
ZA 9609176 A 19980624 ZA 969176 A 19961031 A61K-000/00 199831
CZ 9801231 A3 19980715 WO 96FR1706 A 19961030 A61K-009/19 199835
CZ 981231 A 19961030
NO 9801967 A 19980630 WO 96FR1706 A 19961030 A61K-009/14 199836
NO 981967 A 19980430
EP 858325 A1 19980819 EP 96937367 A 19961030 A61K-009/19 199837
WO 96FR1706 A 19961030
SK 9800525 A3 19981007 WO 96FR1706 A 19961030 A61K-009/19 199850
SK 98525 A 19961030
BR 9611367 A 19990223 BR 9611367 A 19961030 A61K-009/19 199913
WO 96FR1706 A 19961030
CN 1203527 A 19981230 CN 96198786 A 19961030 A61K-009/19 199920
NZ 321616 A 19990429 NZ 321616 A 19960930 A61K-009/19 199923
HU 9900016 A2 19990628 WO 96FR1706 A 19961030 A61K-009/19 199931
HU 9916 A 19961030
JP 11507945 W 19990713 WO 96FR1706 A 19961030 A61K-009/19 199938
JP 97517912 A 19961030
Priority Applications (No Type Date): FR 9513022 A 19951103
Cited Patents: Jnl.Ref; EP 394045; EP 682944; GB 2021581; JP 2096536; JP 50088215; US 4537883; WO 9323017
Patent Details:
Patent Kind Lan Pg Filing Notes Application Patent
WO 9717064 A1 F 43

Designated States (National): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN
Designated States (Regional): AT BE CH DE DK EA ES FI FR GB GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG

FR 2740686 A1 31
AU 9674990 A Based on WO 9717064
ZA 9609176 A 43
CZ 9801231 A3 Based on WO 9717064
EP 858325 A1 F Based on WO 9717064
Designated States (Regional): AT BE CH DE DK ES FI FR GB GR IE IT LI LT LU LV MC NL PT SE SI
BR 9611367 A Based on WO 9717064
HU 9900016 A2 Based on WO 9717064
JP 11507945 W 44 Based on WO 9717064

Abstract (Basic): WO 9717064 A

Lyophilised pharmaceutical formulation (A) consisting of amorphous and crystalline phases, comprises: (i) a non-protein active ingredient (I); (ii) mannitol (II); and (iii) alanine (III). The weight ratio of (II) : (III) is 0.1-1.

USE - The composition is particularly useful for (I) which are not very stable in aqueous solution. (A) can be administered orally, directly, or orally or parenterally after reconstitution with water.

ADVANTAGE - (A) can be stored at 25-40 deg. C without loss of chemical or biological stability and can be reconstituted by addition of solvent. (II) and (III) have a synergistic stabilising action when used at the specified ratio; this is attributed to existence of the two-phase system.

Dwg.0/2

Title Terms: STABILISED; LYOPHILISE; COMPOSITION; EXIST; MIXTURE; AMORPHOUS ; CRYSTAL; PHASE; CONTAIN; NON; PROTEIN; PHARMACEUTICAL; SYNERGISTIC; COMBINATION; MANNITOL; ALANINE; STABILISED; STABILISED; DRUG; AQUEOUS; SOLUTION

Derwent Class: B05; B07

International Patent Class (Main): A61K-000/00; A61K-009/14; A61K-009/19; A61K-047/42

International Patent Class (Additional): A61K-031/41; A61K-031/425; A61K-047/18; A61K-047/26; A61K-047/42; A61K-047-10

File Segment: CPI

Manual Codes (CPI/A-N): B06-D01; B07-H; B10-A07; B10-B02J; B12-M06; B14-S09

END OF DOCUMENT